A 60-year-old ex-smoker with stable COPD (post-bronchodilator FEV1 55% predicted) remains symptomatic with dyspnoea despite using short-acting salbutamol. He has had one moderate exacerbation in the past year. According to COPD-X, what is the most appropriate pharmacological step-up?